Outcomes of allogeneic hematopoietic stem cell transplantation in children and adults with prior invasive fungal diseases

Marina O. Popova 1, Alisa G. Volkova 1, Inna V. Markova 1, Oksana V. Ayzsilnieks 1, Yulia A. Rogacheva 1, Anastasia S. Frolova 1, Aleksandr N. Shvetcov 1, Ilya Y. Nikolaev 1, Svetlana M. Ignatyeva 2, Tatyana S. Bogomolova 2, Asmic G. Gevorgian 1, Olesya V. Paina 1, Tatiana A. Bykova 1, Elena I. Darskaya 1, Maria V. Vladovskaya 1, Ivan S. Moiseev 1, Ludmila S. Zubarovskaya 1, Nikolay N. Klimko 1,2, Boris V. Afanasyev 1 1 Raisa Gorbacheva Memorial Research Institute of Pediatric Oncology, Hematology and Transplantation, Chair of Hematology, Transfusiology and Transplantology, Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia 2 Dept. of Clinical Mycology, I. Mechnikov North-Western State Medical University, St. Petersburg, Russia Outcomes of allogeneic hematopoietic stem cell transplantation in children and adults with prior invasive fungal diseases

[1]  S. Montoto,et al.  The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies , 2019, Bone Marrow Transplantation.

[2]  I. Moiseev,et al.  Different risk factors of acute and chronic graft-versus-host disease with conventional prophylaxis and posttransplantation cyclophosphamide in matched related and unrelated donor transplantations , 2018, Cellular Therapy and Transplantation.

[3]  D. Alexander,et al.  Acute GVHD prophylaxis with posttransplant cyclophosphamide after hematopoietic stem cell transplantation (HSCT) for non-malignant disorders , 2018 .

[4]  N. NKlimko,et al.  СОЧЕТАНИЕ ИНВАЗИВНОГО АСПЕРГИЛЛЕЗА И МУКОРМИКОЗА У ОНКОГЕМАТОЛОГИЧЕСКИХ БОЛЬНЫХ // COMBINATION OF INVASIVE ASPERGILLOSIS AND MUCORMYCOSIS IN ONCOHEMATOLOGICAL PATIENTS , 2018 .

[5]  I. Moiseev,et al.  Single-agent post-transplantation cyclophosphamide versus calcineurin-based graft-versus-host disease prophylaxis in matched related bone marrow transplantation , 2017 .

[6]  E. Guinan,et al.  Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR® study , 2016, Bone Marrow Transplantation.

[7]  I. Moiseev,et al.  Allogeneic hematopoietic stem cell transplantation in children and adults with acute lymphoblastic leukemia , 2016 .

[8]  S. Iacobelli,et al.  Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties , 2016, Bone Marrow Transplantation.

[9]  B. Afanasyev,et al.  Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Prior Invasive Aspergillosis , 2015 .

[10]  K. Thursky,et al.  Epidemiology of invasive fungal disease in lymphoproliferative disorders , 2015, Haematologica.

[11]  F. Baron,et al.  Reduced‐intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation , 2015, Cancer.

[12]  A. Kolbin,et al.  Mucormycosis in haematological patients: case report and results of prospective study in Saint Petersburg, Russia , 2014, Mycoses.

[13]  S. Chevret,et al.  Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium--a groupe de recherche respiratoire en réanimation onco-hématologique study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Einsele,et al.  Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study , 2010, Haematologica.

[15]  Thomas J Walsh,et al.  Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  A. Groll,et al.  Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. , 2007, The Journal of antimicrobial chemotherapy.

[17]  N. Ivanova,et al.  [The experience in non-relative allogenic transplantation of stem hemopoietic cells in the Clinic of Bone Marrow Transplantation at I.P. Pavlov St-Petersburg Medical Academy]. , 2007, Terapevticheskii arkhiv.

[18]  R. Storb,et al.  Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  C. Cordonnier,et al.  Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients , 2004, Bone Marrow Transplantation.

[20]  Lawrence Corey,et al.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  D. De Bacquer,et al.  Impact of previous aspergillosis on the outcome of bone marrow transplantation. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  S. Brunet,et al.  Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature. , 1997, Haematologica.